Balaxi Pharmaceuticals Limited · NSE:BALAXI
Balaxi Pharmaceuticals — FY2023 Earnings Presentation
21 slides from Balaxi Pharmaceuticals's earnings presentation, May 29, 2023
Slide 1: Cover letter to NSE: Investor Presentation
May 29, 2023 To, Listing Department, National Stock Exchange of India Limited Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400051 NSE Symbol: BALAXI Dear Sir/Madam, Subject: Investor Presentation In compliance with Regulation 30 of SEBI (Listing Obligations and Di
Slide 2: Balaxi Pharmaceuticals Limited Investor Presentation
Balaxi Pharmaceuticals Limited Branded IPR-driven Pharma Player in Frontier Markets Investor Presentation
Slide 3: Disclaimer
Disclaimer Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, technological risks, and many other factors that could cause our actual
Slide 4: Corporate Snapshot, Financial Highlights, Strategic Roadmap
04 Corporate Snapshot 14 Financial Highlights 19 Strategic Roadmap Balaxi
Slide 5: Branded IPR-based pharma company
Branded IPR-based pharma (Ti ell company Frontier markets leadership in Latin America and Africa Vast portfolio across diverse therapeutic areas Asset light structure for expansion in semi-regulated markets Balaxi
Slide 6: Distribution Expansion and Transformation
Expansion initiated: Nicaragua, Ecuador, Chile (Latin America) 808 product registrations in six countries 700 registrations submitted or in the pipeline Establishing the Company’s first Tele) ea Sare lia pharmaceutical formulation facility in Hyderabad Successful process being replicated in other Di
Slide 7: Key Success Factors
Key Success Factors Market Selection Methodology =" Focus on countries with high-potential economic growth framework Identify non-English speaking countries with similar characteristics Low competitive intensity and potential to establish top-2 position On-ground feedback mechanism allows deep under
Slide 8: Transition from Asset Light to Asset Right
Transition from “Asset Light” to “Asset Right” : Marketing and Market Research Product Product Manufacturing Distribution Identification Registration Existing Operations New Manufacturing Unit As a part of its corporate evolution, Balaxi is moving its business model from Asset Light’ to ‘Asset Right
Slide 9: Investment in Manufacturing Facilities
e e ‘Investment in Manufacturing Facilities Cott e e efe e eo 6@ e e e e Setting up its first pharmaceutical formulation manufacturing unit * ° General Oral Solid Dosage (OSD) and Liquid Injection formulations Targeting demand for high quality products in Latin American markets Allows full backward
Slide 10: Global Footprint
Global Footprint @aTre) @ Existing Market Dominican Republi \ peers Pie ‘ @ Targeted Expansion an Central Guatemala vf ) Honduras wy : agua : aivinan 4, @ Product Sourcing Regions EI Salvador Republic , Ecuador t 2 Ne full Pine “We. . yo Chile Existing/targeted markets have aggregate GDP of $ 400 bi
Slide 11: Key Milestones
Key Milestones Started business supplying white labelled products to customers in Africa Diversified supply chain by Products were sourced from sourcing pharma products Set-up central distribution WHO GMP certified plants from WHO GMI certified warehouse in Guatemala, based in India manufacturers in
Slide 12: Group structure: subsidiaries
Balaxi Global DMCC, Dubai (WOS) Balaxi Balaxi Balaxi Balaxi Balaxi Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare Dominica Guatemala Angola LDA EL Salvador Honduras Central African SRL (WOS) S.A (WOS) (WOS) Republic(WOS Existing subsidiary companies Balaxi Balaxi Beeb | | Proposed
Slide 13: Board of Directors
Ashish Maheshwari Minoshi Maheshwari /Kunal Bhakta Chairman & Managing Director Non-Executive Director Independent Director Founder of the company, first Co-founder, 20 years of Chartered Accountant with 15 years’ generation entrepreneur, rich experience with Balaxi experience, manages First Water |
Slide 14: Strong Leadership Team
Strong Leadership Team Ashish Maheshwari Amol Mantri Chairman & Managing Director CFO Founder of the company, first generation Qualified Chartered Accountant and Certified Public entrepreneur, qualified Chartered Accountant Accountant from USA Commenced business by supplying white labelled Associate
Slide 15: Financial Highlights
FINANCIAL HIGHLIGHTS Balaxi
Slide 16: Management's Comments
Management’s Comments oo “In FY23, despite the tough operating environment marked by geo-political upheavals, inflationary trends, impact of global pandemic, supply chain issues, and currency depreciation, we have strategically focused on our newly launched geographies in the Latin American markets
Slide 17: Financial Performance (Consolidated)
Financial Performance (Consolidated) Particulars (INR Crore) ae Revenue ve cE WL Gross Margin % 30.0% EBITDA 55.18 EBITDA Margin % Ley Profit After Tax rW As: PAT Margin % rea Tea eee hay) 47.66 NOTE: Financial Results for FY23 are not strictly comparable with FY22 due to the consolidation of Balaxi
Slide 18: Financial Performance Commentary
Financial Performance Commentary Revenue \ =" Higher contribution from the pharmaceuticals business led to y-o-y growth of 20% in revenues for FY23 compared to FY22. The share of LATAM markets increased to 40% of pharmaceutical revenues, highlighting our ability to quickly expand geographical presen
Slide 19: Pharma Product Mix — FY23
Pharma Product Mix — FY23 Geographies Products m Africa* = Branded =m LATAM** = Generics Therapeutic Areas a Dosage Forms = Tablets m Antibiotics = Injectables = Analgesic = Liquids w Anti-malaria Ts = Capsules = Others = Others Balaxi * Africa: Angola and Central African Republic *LATAM — Guatemala
Slide 20: Core Strategy: Enter, Expand & Excel
Core Strategy: Enter, Expand & Excel oan Balaxi in 2020: Business Consolidation ; . = Presence across Angola, Guatemala and Dominican Republic = Effective and efficient supply chain model consisting of 38 warehouses and a fleet of owned vehicles Balaxi in 2021-23: Expansion into New Geographies = Ai
Slide 21: Our Offerings / Thank You
Our Offerings mee Ly a Balaxi aie - —_ “Th na Pharmaceuticals Limited Medical Device i, Ohana Wiheet ania ; = | -Anti-Emetic Plot No. 409, H.No. 8-2-293, 2nd Floor Maps Towers, Jubilee Hills, Road No:81,Hyderabad. Bronchodilator Telangana creel (19) sTuNctiO} Refer WNIT toaar aN ali) : OnE CIN: L251
Balaxi Pharmaceuticals — FY2023 Earnings Presentation on 6ix